Adding immunotherapy to chemotherapy for advanced throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell carcinoma of the larynx or hypopharynx that is locally advanced (has not spread to distant parts of the body).
- Your treatment plan includes removal of the entire voice box (total laryngectomy).
- You have not had radiation therapy to the head or neck before.
- You have not taken immunotherapy (such as a PD-1 inhibitor) before.
- You are in generally good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy combined with an immunotherapy drug (finotonlimab) before surgery for locally advanced hypopharyngeal cancer. It aims to shrink the tumor enough to improve surgery outcomes.
This trial tests whether adding immunotherapy before surgery, followed by either radiation or organ-preserving surgery, can improve outcomes for people with locally advanced laryngeal or hypopharyngeal cancer. It may help avoid complete removal of the voice box.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This study tests a new treatment approach for head and neck cancer that can't be removed with surgery. You would get a combination of an immunotherapy drug (which helps your immune system fight cancer) and chemotherapy first, followed by the standard chemoradiation therapy.
Hear when a new Laryngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.